Bavarian Nordic (OTCMKTS:BVNRY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Maxim Group cut Bavarian Nordic from a “buy” rating to a “hold” rating in a research note on Friday, September 15th.

Shares of Bavarian Nordic (OTCMKTS BVNRY) remained flat at $$12.87 during mid-day trading on Wednesday. 90 shares of the stock traded hands, compared to its average volume of 73. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1,240.00, a P/E ratio of 35.75 and a beta of 0.49. Bavarian Nordic has a one year low of $10.57 and a one year high of $22.70.

TRADEMARK VIOLATION NOTICE: “Bavarian Nordic (BVNRY) Downgraded by Zacks Investment Research to “Sell”” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/29/bavarian-nordic-bvnry-downgraded-by-zacks-investment-research-to-sell-2.html.

About Bavarian Nordic

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Get a free copy of the Zacks research report on Bavarian Nordic (BVNRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.